Siplizumab for Liver Transplant Tolerance

(

PEARL

)

ITN Protocol #:

ITN100ST

Branded Name:

PEARL

ClinicalTrials.Gov ID:

Treatment Protocol #:

Therapeutic Area:

Transplantation

Current Status:

Development

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Promoting Exhaustion and Regulation in in Liver Transplantation using Siplizumab

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Clinical Trial Physician

NIAID Project Manager

NIAID Regulator Officer

Rho Scientist

Study Personnel:

Protocol Chair

James Markmann, MD PhD James.Markmann@pennmedicine.upenn.edu

Work:

215-662-4083

Protocol Chair

Audrey Plough aplough@immunetolerance.org

Work:

415-278-0709

Protocol Chair

Geo Gaile ggaile@immunetolerance.org

Work:

415-854-7485

Protocol Chair

Cynthia Breeden, MPH cbreeden@immunetolerance.org

Work:

404-379-5811

Protocol Chair

Sindhu Chandran, MD schandran@immunetolerance.org

Work:

415-610-4284

Protocol Chair

Merideth Brown Shifflett brownmeri@niaid.nih.gov

Work:

240-627-3483

Protocol Chair

Lyudmila Lyakh lyudmill@mail.nih.gov

Work:

240-627-3530

Protocol Chair

Jaclyn Simpkins jaclyn.simpkins@ppd.com

Work:

757-355-1721